LIFECORE BIOMEDICAL, INC. Proceeds from Divestiture of Businesses
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Divestiture of Businesses of $0 for the 12-month period ending 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for the quarter ending 2022-11-27 was $0.00.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for the quarter ending 2022-08-28 was $3.13M.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for the quarter ending 2022-05-29 was $0.00.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for the quarter ending 2022-02-27 was $73.50M.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for fiscal 2023 was $16.67M, a 77.32% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for fiscal 2022 was $73.50M.
- LIFECORE BIOMEDICAL, INC. proceeds from divestiture of businesses for fiscal 2021 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|
| 2024-05-26 | $0.00 10-K · filed 2024-08-26 | |||
| 2023-11-26 | $0.00 10-Q · filed 2024-08-09 | |||
| 2023-05-28 | $16.67M 10-K · filed 2024-08-26 | |||
| 2022-11-27 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-09 | $3.13M 10-Q · filed 2024-08-09 | $3.13M derived: sum of 3 quarters · filed 2024-08-26 | $76.64M derived: sum of 4 quarters · filed 2024-08-26 |
| 2022-08-28 | $3.13M 10-Q/A · filed 2023-03-16 | $3.13M derived: sum of 2 quarters · filed 2024-08-26 | $76.64M derived: sum of 3 quarters · filed 2024-08-26 | $76.64M derived: sum of 4 quarters · filed 2024-08-26 |
| 2022-05-29 | $0.00 derived: 10-K 12 month − 10-K/A 9 month · filed 2024-08-26 | $73.50M derived: sum of 2 quarters · filed 2024-08-26 | $73.50M derived: sum of 3 quarters · filed 2024-08-26 | $73.50M 10-K · filed 2024-08-26 |
| 2022-02-27 | $73.50M derived: 10-K/A 9 month − 10-Q 6 month · filed 2023-03-16 | $73.50M derived: sum of 2 quarters · filed 2023-03-16 | $73.50M 10-K/A · filed 2023-03-16 | $73.50M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-11-28 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-03-16 | $0.00 10-Q · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | |
| 2021-08-29 | $0.00 10-Q/A · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | ||
| 2021-05-30 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 10-K/A · filed 2023-03-16 | ||
| 2021-02-28 | $0.00 10-Q · filed 2022-04-07 | |||
| 2020-05-31 | $0.00 10-K/A · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |